Product Information

GVOKE PFS 2-PK 1 MG/0.2 ML SYR is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1607.2875 per ML under NDC 72065013112. Its NADAC has been published 258 times since May 20, 2020.

GVOKE PFS 2-PK 1 MG/0.2 ML SYR

glucagon injection, solution
$1607.2875per ML

Strength

1 mg/.2mL

NDC

72065013112

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

2/1/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has been published 258 times since May 20, 2020, and over the history we have for it it has risen 19.9%. The table below summarizes its recorded NADAC range and movement.

Current price$1607.2875 per ML
All-time high$1607.2875 (Jun 24, 2026)
All-time low$1340.0286 (May 20, 2020)
52-week high$1607.2875
52-week low$1558.6875
Median price$1467.6231
Average price$1487.3316
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked258
Tracking sinceMay 20, 2020

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+3.0%

1Y

+3.1%

3Y

+9.5%

5Y

+19.9%

All

+19.9%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 1%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE PFS 2-PK 1 MG/0.2 ML SYR, manufactured by Xeris Pharmaceuticals, Inc., is $1607.2875 per ML (NDC 72065013112), effective Jun 24, 2026.

How has the price of GVOKE PFS 2-PK 1 MG/0.2 ML SYR changed over time?

Over the history we have for it, the NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has risen 19.9%. It has been tracked across 258 weekly CMS publications since May 20, 2020.

What are the highest and lowest recorded NADAC prices for GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

Since May 20, 2020, the NADAC for GVOKE PFS 2-PK 1 MG/0.2 ML SYR has ranged from a low of $1340.0286 (May 20, 2020) to a high of $1607.2875 (Jun 24, 2026), with a median of $1467.6231 per ML.

Are there cheaper alternatives to GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, GVOKE HYPOPEN 2-PK 1 MG/0.2 ML, is $1597.9517 per ML — about 1% below GVOKE PFS 2-PK 1 MG/0.2 ML SYR.

Who manufactures GVOKE PFS 2-PK 1 MG/0.2 ML SYR?

GVOKE PFS 2-PK 1 MG/0.2 ML SYR (NDC 72065013112) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.